Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Роль и место цефиксима в амбулаторной практике уролога (обзор литературы и клиническое наблюдение)
Роль и место цефиксима в амбулаторной практике уролога (обзор литературы и клиническое наблюдение)
Кульчавеня Е.В. Роль и место цефиксима в амбулаторной практике уролога (обзор литературы и клиническое наблюдение). Consilium Medicum. Хирургия (Прил.). 2016; 1: 26–30.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Роль инфекций мочевыводящих путей (ИМП) в последние годы возрастает, и подбор оптимальной антибактериальной терапии имеет первостепенное значение. Проведен обзор современной (после 2011 г.) отечественной и зарубежной литературы по резистентности основных уропатогенов и эффективности цефиксима в лечении ИМП. Показано, что цефиксим – оптимальный антибиотик при урогенитальных инфекциях у разных категорий населения: детей, беременных, иммуносупрессивных пациентов. Следует отметить у цефиксима еще один очень важный положительный эффект – этот антибактериальный препарат не маскирует урогенитальный туберкулез и, соответственно, не затягивает его диагностику. Данный тезис иллюстрируется клиническим примером.
Ключевые слова: инфекции мочевыводящих путей, цистит, бессимптомная бактериурия, беременные, Escherichia coli, лечение, диагностика, антибактериальная терапия, цефиксим.
Key words: urinary tract infections, cystitis, asymptomatic bacteriuria, pregnancy, Escherichia coli, treatment, diagnosis, antibiotic therapy, cefixime.
Ключевые слова: инфекции мочевыводящих путей, цистит, бессимптомная бактериурия, беременные, Escherichia coli, лечение, диагностика, антибактериальная терапия, цефиксим.
________________________________________________
Key words: urinary tract infections, cystitis, asymptomatic bacteriuria, pregnancy, Escherichia coli, treatment, diagnosis, antibiotic therapy, cefixime.
Полный текст
Список литературы
1. Синякова Л.А., Косова И.В. Антимикробная терапия неосложненных инфекций мочевых путей. Consilium Medicum. 2014; 16 (7): 29–33. / Siniakova L.A., Kosova I.V. Antimikrobnaia terapiia neoslozhnennykh infektsii mochevykh putei. Consilium Medicum. 2014; 16 (7): 29–33. [in Russian]
2. Кульчавеня Е.В., Холтобин Д.П. Причины позднего выявления туберкулеза мочевого пузыря. Урология. 2015; 3: 29–32. / Kul'chavenia E.V., Kholtobin D.P. Prichiny pozdnego vyiavleniia tuberkuleza mochevogo puzyria. Urologiia. 2015; 3: 29–32. [in Russian]
3. Перепанова Т.С., Козлов Р.С., Дехнич А.В. и др. Выбор антимикробных препаратов при инфекции мочевыводящих путей. Урология. 2012; 2: 4–8. / Perepanova T.S., Kozlov R.S., Dekhnich A.V. i dr. Vybor antimikrobnykh preparatov pri infektsii mochevyvodiashchikh putei. Urologiia. 2012; 2: 4–8. [in Russian]
4. Кульчавеня Е.В., Чередниченко А.Г., Неймарк А.И., Шевченко С.Ю. Частота встречаемости госпитальных уропатогенов и динамика их чувствительности. Урология. 2015; 2: 13–6. / Kul'chavenia E.V., Cherednichenko A.G., Neimark A.I., Shevchenko S.Iu. Chastota vstrechaemosti gospital'nykh uropatogenov i dinamika ikh chuvstvitel'nosti. Urologiia. 2015; 2: 13–6. [in Russian]
5. Qiao LD, Chen S, Yang Y et al. Characteristics of urinary tract infection pathogens and their in vitro susceptibility to antimicrobial agents in China: data from a multicenter study. BMJ Open 2013; 3 (12): e004152. Doi: 10.1136/bmjopen-2013-004152.
6. Bashir S, Sarwar Y, Ali A, Mohsin M et al. Multiple drug resistance patterns in various phylogenetic groups of uropathogenic E. coli isolated from Faisalabad region of Pakistan. Braz J Microbiol 2011; 42 (4): 1278–83. Doi: 10.1590/S1517-83822011000400005. Epub 2011 Dec 1.
7. Malmartel A, Ghasarossian C. Epidemiology of urinary tract infections, bacterial species and resistances in primary care in France. Eur J Clin Microbiol Infect Dis 2016; 35 (3): 447–51. Doi: 10.1007/s10096-015-2560-1. Epub 2016 Jan 6.
8. Martin D, Fougnot S, Grobost F et al. Prevalence of extended-spectrum beta-lactamase producing Escherichia coli in community-onset urinary tract infections in France in 2013. J Infect 2016; 72 (2): 201–6. Doi: 10.1016/j.jinf.2015.11.009. Epub 2015 Dec 15.
9. Dreshaj Sh, Doda-Ejupi T, Tolaj IQ et al. Clinical role of Cefixime in community-acquired infections. Prilozi 2011; 32 (2): 143–55.
10. Mirsoleymani SR, Salimi M, Shareghi Brojeni M et al. Bacterial pathogens and antimicrobial resistance patterns in pediatric urinary tract infections: a four-year surveillance study (2009–2012). Int J Pediatr 2014; 2014: 126142. Doi: 10.1155/2014/126142. Epub 2014 May 19.
11. Qiao LD, Chen S, Yang Y et al. Characteristics of urinary tract infection pathogens and their in vitro susceptibility to antimicrobial agents in China: data from a multicenter study. BMJ Open 2013; 3 (12): e004152. Doi: 10.1136/bmjopen-2013-004152.
12. Kresken M, Pfeifer Y, Hafner D et al. Working Party ‘Antimicrobial Resistance’ of the Paul-Ehrlich-Society for Chemotherapy. Occurrence of multidrug resistance to oral antibiotics among Escherichia coli urine isolates from outpatient departments in Germany: extended-spectrum b-lactamases and the role of fosfomycin. Int J Antimicrob Agents 2014; 44 (4): 295–300. Doi: 10.1016/j.ijantimicag.2014.05.020. Epub 2014 Jul 16.
13. Majumder MI, Ahmed T, Hossain D, Begum SA. Bacteriology and antibiotic sensitivity patterns of urinary tract infections in a tertiary hospital in Bangladesh. Mymensingh Med J 2014; 23 (1): 99–104.
14. Ahangarkani F, Rajabnia R, Shahandashti EF et al. Frequency of class 1 integron in Escherichia coli strains isolated from patients with urinary tract infections in north of Iran. Mater Sociomed 2015; 27 (1): 10–2. Doi: 10.5455/msm.2014.27.10-12. Epub 2015 Feb 21.
15. Farshad S, Ranjbar R, Japoni A et al. Microbial susceptibility, virulence factors, and plasmid profiles of uropathogenic Escherichia coli strains isolated from children in Jahrom, Iran. Arch Iran Med 2012; 15 (5): 312–6. Doi: 012155/AIM.0013.
16. Pourakbari B, Ferdosian F, Mahmoudi S et al. Increase resistant rates and ESBL production between E. coli isolates causing urinary tract infection in young patients from Iran. Braz J Microbiol 2012; 43 (2): 766–9. Doi: 10.1590/S1517-83822012000200041. Epub 2012 Jun 1.
17. Shill MC, Huda NH, Moain FB, Karmakar UK. Prevalence of uropathogens in diabetic patients and their corresponding resistance pattern: results of a survey conducted at diagnostic centers in Dhaka, Bangladesh. Oman Med J 2010; 25 (4): 282–5. Doi: 10.5001/omj.2010.82.
18 Alizadeh Taheri P, Navabi B, Khatibi E. Frequency and Susceptibility of Bacteria Caused Urinary Tract Infection in Neonates: Eight-Year Study at Neonatal Division of Bahrami Children's Hospital, Tehran Iran. Iran J Public Health 2013; 42 (10): 1126–33.
19. Lewis DA, Gumede LY, Van der Hoven LA et al. Antimicrobial susceptibility of organisms causing community-acquired urinary tract infections in Gauteng Province, South Africa. S Afr Med J 2013; 103 (6): 377–81. Doi: 10.7196/samj.6722.
20. Рафальский В.В., Довгань Е.В., Деревицкий А.В. Цефиксим: клиническая фармакология и место в терапии инфекций урогенитального тракта. Урология. 2011; 2: 63–6. / Rafal'skii V.V., Dovgan' E.V., Derevitskii A.V. Tsefiksim: klinicheskaia farmakologiia i mesto v terapii infektsii urogenital'nogo trakta. Urologiia. 2011; 2: 63–6. [in Russian]
21. Галкин В.В., Довгань Е.В., Козлов С.Н., Рафальский В.В. Цефиксим в сравнении с ципрофлоксацином при остром неосложненном цистите: клинико-экономическое исследование. Клин. микробиология и антимикробная химиотерапия. 2012; 14 (1): 59–66. / Galkin V.V., Dovgan' E.V., Kozlov S.N., Rafal'skii V.V. Tsefiksim v sravnenii s tsiprofloksatsinom pri ostrom neoslozhnennom tsistite: kliniko-ekonomicheskoe issledovanie. Klin. mikrobiologiia i antimikrobnaia khimioterapiia. 2012; 14 (1): 59–66. [in Russian]
22. Галкин В.В., Малев И.В., Довгань Е.В. и др. Эффективность и безопасность цефиксима и ципрофлоксацина при остром цистите (многоцентровое рандомизированное исследование). Урология. 2011 (1): 13–6. / Galkin V.V., Malev I.V., Dovgan' E.V. i dr. Effektivnost' i bezopasnost' tsefiksima i tsiprofloksatsina pri ostrom tsistite (mnogotsentrovoe randomizirovannoe issledovanie). Urologiia. 2011 (1): 13–6. [in Russian]
23. Коровина Н.А., Мумладзе Э.Б., Захарова И.Н. и др. Пероральные цефалоспорины III поколения при воспалительных заболеваниях органов мочевой системы у детей. Consilium Medicum. Педиатрия (Прил.). 2005; 2: 17–20. / Korovina N.A., Mumladze E.B., Zakharova I.N. i dr. Peroral'nye tsefalosporiny III pokoleniia pri vospalitel'nykh zabolevaniiakh organov mochevoi sistemy u detei. Consilium Medicum. Pediatrics (Suppl.). 2005; 2: 17–20. [in Russian]
24. Леженко Г.А., Пашкова Е.Е., Рудова Е.И., Рубанова Е.И. Опыт применения цефиксима в лечении инфекций мочевой системы у детей. Соврем. педиатрия. 2013; 4 (52): 152. / Lezhenko G.A., Pashkova E.E., Rudova E.I., Rubanova E.I. Opyt primeneniia tsefiksima v lechenii infektsii mochevoi sistemy u detei. Sovrem. pediatriia. 2013; 4 (52): 152. [in Russian]
25. Sedighi I, Solgi A, Amanati A, Alikhani MY. Choosing the correct empirical antibiotic for urinary tract infection in pediatric: Surveillance of antimicrobial susceptibility pattern of Escherichia coli by E-Test method. Iran J Microbiol 2014; 6 (6): 387–91.
26. Çoban B, Ülkü N, Kaplan H et al. Five-year assessment of causative agents and antibiotic resistances in urinary tract infections. Turk Pediatri Ars 2014; 49 (2): 124–9. Doi: 10.5152/tpa.2014.1505. eCollection 2014 Jun.
27. Лоран О.Б., Коган М.И., Синякова Л.А. и др. Рациональная терапия рецидивирующих инфекций нижних мочевыводящих путей. Результаты проспективной наблюдательной программы по оценке эффективности и безопасности применения препаратов Цефорал® Солютаб® и Уро-Васком® у пациенток с рецидивирующими неосложненными инфекциями нижних мочевыводящих путей (FLORA). Урология. 2015; 4: 11–8. / Loran O.B., Kogan M.I., Siniakova L.A. i dr. Ratsional'naia terapiia retsidiviruiushchikh infektsii nizhnikh mochevyvodiashchikh putei. Rezul'taty prospektivnoi nabliudatel'noi programmy po otsenke effektivnosti i bezopasnosti primeneniia preparatov Tseforal® Soliutab® i Uro-Vaskom® u patsientok s retsidiviruiushchimi neoslozhnennymi infektsiiami nizhnikh mochevyvodiashchikh putei (FLORA). Urologiia. 2015; 4: 11–8. [in Russian]
28. Кульчавеня Е.В., Бреусов А.А. Эффективность уро-ваксома при рецидивирующих инфекционно-воспалительных заболеваниях мочеполовой системы. Урология. 2011; 4: 7–11. / Kul'chavenia E.V., Breusov A.A. Effektivnost' uro-vaksoma pri retsidiviruiushchikh infektsionno-vospalitel'nykh zabolevaniiakh mochepolovoi sistemy. Urologiia. 2011; 4: 7–11. [in Russian]
29. Pistiki A, Tsaganos T, Galani I, Giamarellos-Bourboulis EJ. In Vitro Activity of Oral Cephalosporins (Cefprozil and Cefixime) Against Ciprofloxacin-Resistant Enterobacteriaceae from Community-Acquired Urinary-Tract Infections. Infect Dis Ther 2015; 4 (4): 425–32. Doi: 10.1007/s40121-015-0089-3. Epub 2015 Sep 21.
30. Rezai MS, Salehifar E, Rafiei A et al. Characterization of Multidrug Resistant Extended-Spectrum Beta-Lactamase-Producing Escherichia coli among Uropathogens of Pediatrics in North of Iran. Biomed Res Int 2015; 2015: 309478. Doi: 10.1155/2015/309478. Epub 2015 May 3.
31. Фомин В.В. Место цефиксима в лечении инфекций мочевыводящей системы. Фарматека. 2011; 15: 69–72. / Fomin V.V. Mesto tsefiksima v lechenii infektsii mochevyvodiashchei sistemy. Farmateka. 2011; 15: 69–72. [in Russian]
32. Козырев Ю.В., Густоварова Т.А. Бессимптомная бактериурия у беременных. Вестн. Смоленской государственной медицинской академии. 2011; 4: 36–42. / Kozyrev Iu.V., Gustovarova T.A. Bessimptomnaia bakteriuriia u beremennykh. Vestn. Smolenskoi gosudarstvennoi meditsinskoi akademii. 2011; 4: 36–42. [in Russian]
33. Рафальский В.В., Довгань Е.В., Козырев Ю.В. и др. Эффективность и безопасность цефиксима и амоксициллина/клавуланата при лечении бессимптомной бактериурии у беременных: многоцентровое рандомизированное проспективное исследование. Урология. 2013; 5: 24–9. / Rafal'skii V.V., Dovgan' E.V., Kozyrev Iu.V. i dr. Effektivnost' i bezopasnost' tsefiksima i amoksitsillina/klavulanata pri lechenii bessimptomnoi bakteriurii u beremennykh: mnogotsentrovoe randomizirovannoe prospektivnoe issledovanie. Urologiia. 2013; 5: 24–9. [in Russian]
34. Гелашвили В.В., Спивак Л.Г., Демидко Ю.Л. Медикаментозная профилактика рецидивов хронической инфекции мочевого пузыря. Вопр. урологии и андрологии. 2014; 3 (3): 31–33. / Gelashvili V.V., Spivak L.G., Demidko Iu.L. Medikamentoznaia profilaktika retsidivov khronicheskoi infektsii mochevogo puzyria. Vopr. urologii i andrologii. 2014; 3 (3): 31–33. [in Russian]
35. Moustafa F, Nguyen G, Mathevon T et al. Evaluation of the efficacy and tolerance of a short 7 day third-generation cephalosporin treatment in the management of acute pyelonephritis in young women in the emergency department. J Antimicrob Chemother 2016; pii: dkw021. [Epub ahead of print].
36. Bingen E, Bidet P, Birgy A et al. In vitro interaction between cefixime and amoxicillin-clavulanate against extended-spectrum-beta-lactamase-producing Escherichia coli causing urinary tract infection. J Clin Microbiol 2012; 50 (7): 2540–1. Doi: 10.1128/JCM.00526-12. Epub 2012 Apr 25.
37. Madhi F, Biscardi S, Bingen E et al. Combined relay therapy with oral cefixime and clavulanate for febrile urinary tract infection caused by extended-spectrum b-lactamase-producing Escherichia coli. Pediatr Infect Dis J 2013; 32 (1): 96–7. Doi: 10.1097/INF.0b013e318271f369.
38. Khosravi AD, Abasi Montazeri E, Ghorbani A, Parhizgari N. Bacterial urinary tract infection in renal transplant recipients and their antibiotic resistance pattern: A four-year study. Iran J Microbiol 2014; 6 (2): 74–8.
39. Bayram E, Bayram MT, Hiz S, Turkmen M. Cefixime-induced oculogyric crisis. Pediatr Emerg Care 2012; 28 (1): 55–6. Doi: 10.1097/PEC.0b013e31823f252d.
40. Williams GJ, Wei L, Lee A, Craig JC. Long-term antibiotics for preventing recurrent urinary tract infection in children. Cochrane Database Syst Rev 2006; 3: CD001534.
41. Кульчавеня Е.В., Краснов В.А., Скорняков С.Н. и др. Современные тенденции эпидемической ситуации по внеторакальному туберкулезу. Туберкулез и болезни легких. 2013; 12: 34–8. / Kul'chavenia E.V., Krasnov V.A., Skorniakov S.N. i dr. Sovremennye tendentsii epidemicheskoi situatsii po vnetorakal'nomu tuberkulezu. Tuberkulez i bolezni legkikh. 2013; 12: 34–8. [in Russian]
42. Кульчавеня Е.В., Брижатюк Е.В., Ковешникова Е.Ю., Свешникова Н.Н. Новые тенденции в эпидемической ситуации по туберкулезу экстраторакальных локализаций в Сибири и на Дальнем Востоке. Туберкулез и болезни легких. 2009; 10: 27–31. / Kul'chavenia E.V., Brizhatiuk E.V., Koveshnikova E.Iu., Sveshnikova N.N. Novye tendentsii v epidemicheskoi situatsii po tuberkulezu ekstratorakal'nykh lokalizatsii v Sibiri i na Dal'nem Vostoke. Tuberkulez i bolezni legkikh. 2009; 10: 27–31. [in Russian]
43. Кульчавеня Е.В., Чередниченко А.Г., Баранчукова А.А. Диагностика урогенитального туберкулеза. Урология. 2015; 5: 124–8. / Kul'chavenia E.V., Cherednichenko A.G., Baranchukova A.A. Diagnostika urogenital'nogo tuberkuleza. Urologiia. 2015; 5: 124–8. [in Russian]
44. Кульчавеня Е.В. Терапия ex juvantibus в дифференциальной диагностике туберкулеза мочеполовой системы. Туберкулез и болезни легких. 2001; 2: 29. / Kul'chavenia E.V. Terapiia ex juvantibus v differentsial'noi diagnostike tuberkuleza mochepolovoi sistemy. Tuberkulez i bolezni legkikh. 2001; 2: 29. [in Russian]
2. Kul'chavenia E.V., Kholtobin D.P. Prichiny pozdnego vyiavleniia tuberkuleza mochevogo puzyria. Urologiia. 2015; 3: 29–32. [in Russian]
3. Perepanova T.S., Kozlov R.S., Dekhnich A.V. i dr. Vybor antimikrobnykh preparatov pri infektsii mochevyvodiashchikh putei. Urologiia. 2012; 2: 4–8. [in Russian]
4. Kul'chavenia E.V., Cherednichenko A.G., Neimark A.I., Shevchenko S.Iu. Chastota vstrechaemosti gospital'nykh uropatogenov i dinamika ikh chuvstvitel'nosti. Urologiia. 2015; 2: 13–6. [in Russian]
5. Qiao LD, Chen S, Yang Y et al. Characteristics of urinary tract infection pathogens and their in vitro susceptibility to antimicrobial agents in China: data from a multicenter study. BMJ Open 2013; 3 (12): e004152. Doi: 10.1136/bmjopen-2013-004152.
6. Bashir S, Sarwar Y, Ali A, Mohsin M et al. Multiple drug resistance patterns in various phylogenetic groups of uropathogenic E. coli isolated from Faisalabad region of Pakistan. Braz J Microbiol 2011; 42 (4): 1278–83. Doi: 10.1590/S1517-83822011000400005. Epub 2011 Dec 1.
7. Malmartel A, Ghasarossian C. Epidemiology of urinary tract infections, bacterial species and resistances in primary care in France. Eur J Clin Microbiol Infect Dis 2016; 35 (3): 447–51. Doi: 10.1007/s10096-015-2560-1. Epub 2016 Jan 6.
8. Martin D, Fougnot S, Grobost F et al. Prevalence of extended-spectrum beta-lactamase producing Escherichia coli in community-onset urinary tract infections in France in 2013. J Infect 2016; 72 (2): 201–6. Doi: 10.1016/j.jinf.2015.11.009. Epub 2015 Dec 15.
9. Dreshaj Sh, Doda-Ejupi T, Tolaj IQ et al. Clinical role of Cefixime in community-acquired infections. Prilozi 2011; 32 (2): 143–55.
10. Mirsoleymani SR, Salimi M, Shareghi Brojeni M et al. Bacterial pathogens and antimicrobial resistance patterns in pediatric urinary tract infections: a four-year surveillance study (2009–2012). Int J Pediatr 2014; 2014: 126142. Doi: 10.1155/2014/126142. Epub 2014 May 19.
11. Qiao LD, Chen S, Yang Y et al. Characteristics of urinary tract infection pathogens and their in vitro susceptibility to antimicrobial agents in China: data from a multicenter study. BMJ Open 2013; 3 (12): e004152. Doi: 10.1136/bmjopen-2013-004152.
12. Kresken M, Pfeifer Y, Hafner D et al. Working Party ‘Antimicrobial Resistance’ of the Paul-Ehrlich-Society for Chemotherapy. Occurrence of multidrug resistance to oral antibiotics among Escherichia coli urine isolates from outpatient departments in Germany: extended-spectrum b-lactamases and the role of fosfomycin. Int J Antimicrob Agents 2014; 44 (4): 295–300. Doi: 10.1016/j.ijantimicag.2014.05.020. Epub 2014 Jul 16.
13. Majumder MI, Ahmed T, Hossain D, Begum SA. Bacteriology and antibiotic sensitivity patterns of urinary tract infections in a tertiary hospital in Bangladesh. Mymensingh Med J 2014; 23 (1): 99–104.
14. Ahangarkani F, Rajabnia R, Shahandashti EF et al. Frequency of class 1 integron in Escherichia coli strains isolated from patients with urinary tract infections in north of Iran. Mater Sociomed 2015; 27 (1): 10–2. Doi: 10.5455/msm.2014.27.10-12. Epub 2015 Feb 21.
15. Farshad S, Ranjbar R, Japoni A et al. Microbial susceptibility, virulence factors, and plasmid profiles of uropathogenic Escherichia coli strains isolated from children in Jahrom, Iran. Arch Iran Med 2012; 15 (5): 312–6. Doi: 012155/AIM.0013.
16. Pourakbari B, Ferdosian F, Mahmoudi S et al. Increase resistant rates and ESBL production between E. coli isolates causing urinary tract infection in young patients from Iran. Braz J Microbiol 2012; 43 (2): 766–9. Doi: 10.1590/S1517-83822012000200041. Epub 2012 Jun 1.
17. Shill MC, Huda NH, Moain FB, Karmakar UK. Prevalence of uropathogens in diabetic patients and their corresponding resistance pattern: results of a survey conducted at diagnostic centers in Dhaka, Bangladesh. Oman Med J 2010; 25 (4): 282–5. Doi: 10.5001/omj.2010.82.
18 Alizadeh Taheri P, Navabi B, Khatibi E. Frequency and Susceptibility of Bacteria Caused Urinary Tract Infection in Neonates: Eight-Year Study at Neonatal Division of Bahrami Children's Hospital, Tehran Iran. Iran J Public Health 2013; 42 (10): 1126–33.
19. Lewis DA, Gumede LY, Van der Hoven LA et al. Antimicrobial susceptibility of organisms causing community-acquired urinary tract infections in Gauteng Province, South Africa. S Afr Med J 2013; 103 (6): 377–81. Doi: 10.7196/samj.6722.
20. Rafal'skii V.V., Dovgan' E.V., Derevitskii A.V. Tsefiksim: klinicheskaia farmakologiia i mesto v terapii infektsii urogenital'nogo trakta. Urologiia. 2011; 2: 63–6. [in Russian]
21. Galkin V.V., Dovgan' E.V., Kozlov S.N., Rafal'skii V.V. Tsefiksim v sravnenii s tsiprofloksatsinom pri ostrom neoslozhnennom tsistite: kliniko-ekonomicheskoe issledovanie. Klin. mikrobiologiia i antimikrobnaia khimioterapiia. 2012; 14 (1): 59–66. [in Russian]
22. Galkin V.V., Malev I.V., Dovgan' E.V. i dr. Effektivnost' i bezopasnost' tsefiksima i tsiprofloksatsina pri ostrom tsistite (mnogotsentrovoe randomizirovannoe issledovanie). Urologiia. 2011 (1): 13–6. [in Russian]
23. Korovina N.A., Mumladze E.B., Zakharova I.N. i dr. Peroral'nye tsefalosporiny III pokoleniia pri vospalitel'nykh zabolevaniiakh organov mochevoi sistemy u detei. Consilium Medicum. Pediatrics (Suppl.). 2005; 2: 17–20. [in Russian]
24. Lezhenko G.A., Pashkova E.E., Rudova E.I., Rubanova E.I. Opyt primeneniia tsefiksima v lechenii infektsii mochevoi sistemy u detei. Sovrem. pediatriia. 2013; 4 (52): 152. [in Russian]
25. Sedighi I, Solgi A, Amanati A, Alikhani MY. Choosing the correct empirical antibiotic for urinary tract infection in pediatric: Surveillance of antimicrobial susceptibility pattern of Escherichia coli by E-Test method. Iran J Microbiol 2014; 6 (6): 387–91.
26. Çoban B, Ülkü N, Kaplan H et al. Five-year assessment of causative agents and antibiotic resistances in urinary tract infections. Turk Pediatri Ars 2014; 49 (2): 124–9. Doi: 10.5152/tpa.2014.1505. eCollection 2014 Jun.
27. Loran O.B., Kogan M.I., Siniakova L.A. i dr. Ratsional'naia terapiia retsidiviruiushchikh infektsii nizhnikh mochevyvodiashchikh putei. Rezul'taty prospektivnoi nabliudatel'noi programmy po otsenke effektivnosti i bezopasnosti primeneniia preparatov Tseforal® Soliutab® i Uro-Vaskom® u patsientok s retsidiviruiushchimi neoslozhnennymi infektsiiami nizhnikh mochevyvodiashchikh putei (FLORA). Urologiia. 2015; 4: 11–8. [in Russian]
28. Kul'chavenia E.V., Breusov A.A. Effektivnost' uro-vaksoma pri retsidiviruiushchikh infektsionno-vospalitel'nykh zabolevaniiakh mochepolovoi sistemy. Urologiia. 2011; 4: 7–11. [in Russian]
29. Pistiki A, Tsaganos T, Galani I, Giamarellos-Bourboulis EJ. In Vitro Activity of Oral Cephalosporins (Cefprozil and Cefixime) Against Ciprofloxacin-Resistant Enterobacteriaceae from Community-Acquired Urinary-Tract Infections. Infect Dis Ther 2015; 4 (4): 425–32. Doi: 10.1007/s40121-015-0089-3. Epub 2015 Sep 21.
30. Rezai MS, Salehifar E, Rafiei A et al. Characterization of Multidrug Resistant Extended-Spectrum Beta-Lactamase-Producing Escherichia coli among Uropathogens of Pediatrics in North of Iran. Biomed Res Int 2015; 2015: 309478. Doi: 10.1155/2015/309478. Epub 2015 May 3.
31. Fomin V.V. Mesto tsefiksima v lechenii infektsii mochevyvodiashchei sistemy. Farmateka. 2011; 15: 69–72. [in Russian]
32. Kozyrev Iu.V., Gustovarova T.A. Bessimptomnaia bakteriuriia u beremennykh. Vestn. Smolenskoi gosudarstvennoi meditsinskoi akademii. 2011; 4: 36–42. [in Russian]
33. Rafal'skii V.V., Dovgan' E.V., Kozyrev Iu.V. i dr. Effektivnost' i bezopasnost' tsefiksima i amoksitsillina/klavulanata pri lechenii bessimptomnoi bakteriurii u beremennykh: mnogotsentrovoe randomizirovannoe prospektivnoe issledovanie. Urologiia. 2013; 5: 24–9. [in Russian]
34. Gelashvili V.V., Spivak L.G., Demidko Iu.L. Medikamentoznaia profilaktika retsidivov khronicheskoi infektsii mochevogo puzyria. Vopr. urologii i andrologii. 2014; 3 (3): 31–33. [in Russian]
35. Moustafa F, Nguyen G, Mathevon T et al. Evaluation of the efficacy and tolerance of a short 7 day third-generation cephalosporin treatment in the management of acute pyelonephritis in young women in the emergency department. J Antimicrob Chemother 2016; pii: dkw021. [Epub ahead of print].
36. Bingen E, Bidet P, Birgy A et al. In vitro interaction between cefixime and amoxicillin-clavulanate against extended-spectrum-beta-lactamase-producing Escherichia coli causing urinary tract infection. J Clin Microbiol 2012; 50 (7): 2540–1. Doi: 10.1128/JCM.00526-12. Epub 2012 Apr 25.
37. Madhi F, Biscardi S, Bingen E et al. Combined relay therapy with oral cefixime and clavulanate for febrile urinary tract infection caused by extended-spectrum b-lactamase-producing Escherichia coli. Pediatr Infect Dis J 2013; 32 (1): 96–7. Doi: 10.1097/INF.0b013e318271f369.
38. Khosravi AD, Abasi Montazeri E, Ghorbani A, Parhizgari N. Bacterial urinary tract infection in renal transplant recipients and their antibiotic resistance pattern: A four-year study. Iran J Microbiol 2014; 6 (2): 74–8.
39. Bayram E, Bayram MT, Hiz S, Turkmen M. Cefixime-induced oculogyric crisis. Pediatr Emerg Care 2012; 28 (1): 55–6. Doi: 10.1097/PEC.0b013e31823f252d.
40. Williams GJ, Wei L, Lee A, Craig JC. Long-term antibiotics for preventing recurrent urinary tract infection in children. Cochrane Database Syst Rev 2006; 3: CD001534.
41. Kul'chavenia E.V., Krasnov V.A., Skorniakov S.N. i dr. Sovremennye tendentsii epidemicheskoi situatsii po vnetorakal'nomu tuberkulezu. Tuberkulez i bolezni legkikh. 2013; 12: 34–8. [in Russian]
42. Kul'chavenia E.V., Brizhatiuk E.V., Koveshnikova E.Iu., Sveshnikova N.N. Novye tendentsii v epidemicheskoi situatsii po tuberkulezu ekstratorakal'nykh lokalizatsii v Sibiri i na Dal'nem Vostoke. Tuberkulez i bolezni legkikh. 2009; 10: 27–31. [in Russian]
43. Kul'chavenia E.V., Cherednichenko A.G., Baranchukova A.A. Diagnostika urogenital'nogo tuberkuleza. Urologiia. 2015; 5: 124–8. [in Russian]
44. Kul'chavenia E.V. Terapiia ex juvantibus v differentsial'noi diagnostike tuberkuleza mochepolovoi sistemy. Tuberkulez i bolezni legkikh. 2001; 2: 29. [in Russian]
2. Кульчавеня Е.В., Холтобин Д.П. Причины позднего выявления туберкулеза мочевого пузыря. Урология. 2015; 3: 29–32. / Kul'chavenia E.V., Kholtobin D.P. Prichiny pozdnego vyiavleniia tuberkuleza mochevogo puzyria. Urologiia. 2015; 3: 29–32. [in Russian]
3. Перепанова Т.С., Козлов Р.С., Дехнич А.В. и др. Выбор антимикробных препаратов при инфекции мочевыводящих путей. Урология. 2012; 2: 4–8. / Perepanova T.S., Kozlov R.S., Dekhnich A.V. i dr. Vybor antimikrobnykh preparatov pri infektsii mochevyvodiashchikh putei. Urologiia. 2012; 2: 4–8. [in Russian]
4. Кульчавеня Е.В., Чередниченко А.Г., Неймарк А.И., Шевченко С.Ю. Частота встречаемости госпитальных уропатогенов и динамика их чувствительности. Урология. 2015; 2: 13–6. / Kul'chavenia E.V., Cherednichenko A.G., Neimark A.I., Shevchenko S.Iu. Chastota vstrechaemosti gospital'nykh uropatogenov i dinamika ikh chuvstvitel'nosti. Urologiia. 2015; 2: 13–6. [in Russian]
5. Qiao LD, Chen S, Yang Y et al. Characteristics of urinary tract infection pathogens and their in vitro susceptibility to antimicrobial agents in China: data from a multicenter study. BMJ Open 2013; 3 (12): e004152. Doi: 10.1136/bmjopen-2013-004152.
6. Bashir S, Sarwar Y, Ali A, Mohsin M et al. Multiple drug resistance patterns in various phylogenetic groups of uropathogenic E. coli isolated from Faisalabad region of Pakistan. Braz J Microbiol 2011; 42 (4): 1278–83. Doi: 10.1590/S1517-83822011000400005. Epub 2011 Dec 1.
7. Malmartel A, Ghasarossian C. Epidemiology of urinary tract infections, bacterial species and resistances in primary care in France. Eur J Clin Microbiol Infect Dis 2016; 35 (3): 447–51. Doi: 10.1007/s10096-015-2560-1. Epub 2016 Jan 6.
8. Martin D, Fougnot S, Grobost F et al. Prevalence of extended-spectrum beta-lactamase producing Escherichia coli in community-onset urinary tract infections in France in 2013. J Infect 2016; 72 (2): 201–6. Doi: 10.1016/j.jinf.2015.11.009. Epub 2015 Dec 15.
9. Dreshaj Sh, Doda-Ejupi T, Tolaj IQ et al. Clinical role of Cefixime in community-acquired infections. Prilozi 2011; 32 (2): 143–55.
10. Mirsoleymani SR, Salimi M, Shareghi Brojeni M et al. Bacterial pathogens and antimicrobial resistance patterns in pediatric urinary tract infections: a four-year surveillance study (2009–2012). Int J Pediatr 2014; 2014: 126142. Doi: 10.1155/2014/126142. Epub 2014 May 19.
11. Qiao LD, Chen S, Yang Y et al. Characteristics of urinary tract infection pathogens and their in vitro susceptibility to antimicrobial agents in China: data from a multicenter study. BMJ Open 2013; 3 (12): e004152. Doi: 10.1136/bmjopen-2013-004152.
12. Kresken M, Pfeifer Y, Hafner D et al. Working Party ‘Antimicrobial Resistance’ of the Paul-Ehrlich-Society for Chemotherapy. Occurrence of multidrug resistance to oral antibiotics among Escherichia coli urine isolates from outpatient departments in Germany: extended-spectrum b-lactamases and the role of fosfomycin. Int J Antimicrob Agents 2014; 44 (4): 295–300. Doi: 10.1016/j.ijantimicag.2014.05.020. Epub 2014 Jul 16.
13. Majumder MI, Ahmed T, Hossain D, Begum SA. Bacteriology and antibiotic sensitivity patterns of urinary tract infections in a tertiary hospital in Bangladesh. Mymensingh Med J 2014; 23 (1): 99–104.
14. Ahangarkani F, Rajabnia R, Shahandashti EF et al. Frequency of class 1 integron in Escherichia coli strains isolated from patients with urinary tract infections in north of Iran. Mater Sociomed 2015; 27 (1): 10–2. Doi: 10.5455/msm.2014.27.10-12. Epub 2015 Feb 21.
15. Farshad S, Ranjbar R, Japoni A et al. Microbial susceptibility, virulence factors, and plasmid profiles of uropathogenic Escherichia coli strains isolated from children in Jahrom, Iran. Arch Iran Med 2012; 15 (5): 312–6. Doi: 012155/AIM.0013.
16. Pourakbari B, Ferdosian F, Mahmoudi S et al. Increase resistant rates and ESBL production between E. coli isolates causing urinary tract infection in young patients from Iran. Braz J Microbiol 2012; 43 (2): 766–9. Doi: 10.1590/S1517-83822012000200041. Epub 2012 Jun 1.
17. Shill MC, Huda NH, Moain FB, Karmakar UK. Prevalence of uropathogens in diabetic patients and their corresponding resistance pattern: results of a survey conducted at diagnostic centers in Dhaka, Bangladesh. Oman Med J 2010; 25 (4): 282–5. Doi: 10.5001/omj.2010.82.
18 Alizadeh Taheri P, Navabi B, Khatibi E. Frequency and Susceptibility of Bacteria Caused Urinary Tract Infection in Neonates: Eight-Year Study at Neonatal Division of Bahrami Children's Hospital, Tehran Iran. Iran J Public Health 2013; 42 (10): 1126–33.
19. Lewis DA, Gumede LY, Van der Hoven LA et al. Antimicrobial susceptibility of organisms causing community-acquired urinary tract infections in Gauteng Province, South Africa. S Afr Med J 2013; 103 (6): 377–81. Doi: 10.7196/samj.6722.
20. Рафальский В.В., Довгань Е.В., Деревицкий А.В. Цефиксим: клиническая фармакология и место в терапии инфекций урогенитального тракта. Урология. 2011; 2: 63–6. / Rafal'skii V.V., Dovgan' E.V., Derevitskii A.V. Tsefiksim: klinicheskaia farmakologiia i mesto v terapii infektsii urogenital'nogo trakta. Urologiia. 2011; 2: 63–6. [in Russian]
21. Галкин В.В., Довгань Е.В., Козлов С.Н., Рафальский В.В. Цефиксим в сравнении с ципрофлоксацином при остром неосложненном цистите: клинико-экономическое исследование. Клин. микробиология и антимикробная химиотерапия. 2012; 14 (1): 59–66. / Galkin V.V., Dovgan' E.V., Kozlov S.N., Rafal'skii V.V. Tsefiksim v sravnenii s tsiprofloksatsinom pri ostrom neoslozhnennom tsistite: kliniko-ekonomicheskoe issledovanie. Klin. mikrobiologiia i antimikrobnaia khimioterapiia. 2012; 14 (1): 59–66. [in Russian]
22. Галкин В.В., Малев И.В., Довгань Е.В. и др. Эффективность и безопасность цефиксима и ципрофлоксацина при остром цистите (многоцентровое рандомизированное исследование). Урология. 2011 (1): 13–6. / Galkin V.V., Malev I.V., Dovgan' E.V. i dr. Effektivnost' i bezopasnost' tsefiksima i tsiprofloksatsina pri ostrom tsistite (mnogotsentrovoe randomizirovannoe issledovanie). Urologiia. 2011 (1): 13–6. [in Russian]
23. Коровина Н.А., Мумладзе Э.Б., Захарова И.Н. и др. Пероральные цефалоспорины III поколения при воспалительных заболеваниях органов мочевой системы у детей. Consilium Medicum. Педиатрия (Прил.). 2005; 2: 17–20. / Korovina N.A., Mumladze E.B., Zakharova I.N. i dr. Peroral'nye tsefalosporiny III pokoleniia pri vospalitel'nykh zabolevaniiakh organov mochevoi sistemy u detei. Consilium Medicum. Pediatrics (Suppl.). 2005; 2: 17–20. [in Russian]
24. Леженко Г.А., Пашкова Е.Е., Рудова Е.И., Рубанова Е.И. Опыт применения цефиксима в лечении инфекций мочевой системы у детей. Соврем. педиатрия. 2013; 4 (52): 152. / Lezhenko G.A., Pashkova E.E., Rudova E.I., Rubanova E.I. Opyt primeneniia tsefiksima v lechenii infektsii mochevoi sistemy u detei. Sovrem. pediatriia. 2013; 4 (52): 152. [in Russian]
25. Sedighi I, Solgi A, Amanati A, Alikhani MY. Choosing the correct empirical antibiotic for urinary tract infection in pediatric: Surveillance of antimicrobial susceptibility pattern of Escherichia coli by E-Test method. Iran J Microbiol 2014; 6 (6): 387–91.
26. Çoban B, Ülkü N, Kaplan H et al. Five-year assessment of causative agents and antibiotic resistances in urinary tract infections. Turk Pediatri Ars 2014; 49 (2): 124–9. Doi: 10.5152/tpa.2014.1505. eCollection 2014 Jun.
27. Лоран О.Б., Коган М.И., Синякова Л.А. и др. Рациональная терапия рецидивирующих инфекций нижних мочевыводящих путей. Результаты проспективной наблюдательной программы по оценке эффективности и безопасности применения препаратов Цефорал® Солютаб® и Уро-Васком® у пациенток с рецидивирующими неосложненными инфекциями нижних мочевыводящих путей (FLORA). Урология. 2015; 4: 11–8. / Loran O.B., Kogan M.I., Siniakova L.A. i dr. Ratsional'naia terapiia retsidiviruiushchikh infektsii nizhnikh mochevyvodiashchikh putei. Rezul'taty prospektivnoi nabliudatel'noi programmy po otsenke effektivnosti i bezopasnosti primeneniia preparatov Tseforal® Soliutab® i Uro-Vaskom® u patsientok s retsidiviruiushchimi neoslozhnennymi infektsiiami nizhnikh mochevyvodiashchikh putei (FLORA). Urologiia. 2015; 4: 11–8. [in Russian]
28. Кульчавеня Е.В., Бреусов А.А. Эффективность уро-ваксома при рецидивирующих инфекционно-воспалительных заболеваниях мочеполовой системы. Урология. 2011; 4: 7–11. / Kul'chavenia E.V., Breusov A.A. Effektivnost' uro-vaksoma pri retsidiviruiushchikh infektsionno-vospalitel'nykh zabolevaniiakh mochepolovoi sistemy. Urologiia. 2011; 4: 7–11. [in Russian]
29. Pistiki A, Tsaganos T, Galani I, Giamarellos-Bourboulis EJ. In Vitro Activity of Oral Cephalosporins (Cefprozil and Cefixime) Against Ciprofloxacin-Resistant Enterobacteriaceae from Community-Acquired Urinary-Tract Infections. Infect Dis Ther 2015; 4 (4): 425–32. Doi: 10.1007/s40121-015-0089-3. Epub 2015 Sep 21.
30. Rezai MS, Salehifar E, Rafiei A et al. Characterization of Multidrug Resistant Extended-Spectrum Beta-Lactamase-Producing Escherichia coli among Uropathogens of Pediatrics in North of Iran. Biomed Res Int 2015; 2015: 309478. Doi: 10.1155/2015/309478. Epub 2015 May 3.
31. Фомин В.В. Место цефиксима в лечении инфекций мочевыводящей системы. Фарматека. 2011; 15: 69–72. / Fomin V.V. Mesto tsefiksima v lechenii infektsii mochevyvodiashchei sistemy. Farmateka. 2011; 15: 69–72. [in Russian]
32. Козырев Ю.В., Густоварова Т.А. Бессимптомная бактериурия у беременных. Вестн. Смоленской государственной медицинской академии. 2011; 4: 36–42. / Kozyrev Iu.V., Gustovarova T.A. Bessimptomnaia bakteriuriia u beremennykh. Vestn. Smolenskoi gosudarstvennoi meditsinskoi akademii. 2011; 4: 36–42. [in Russian]
33. Рафальский В.В., Довгань Е.В., Козырев Ю.В. и др. Эффективность и безопасность цефиксима и амоксициллина/клавуланата при лечении бессимптомной бактериурии у беременных: многоцентровое рандомизированное проспективное исследование. Урология. 2013; 5: 24–9. / Rafal'skii V.V., Dovgan' E.V., Kozyrev Iu.V. i dr. Effektivnost' i bezopasnost' tsefiksima i amoksitsillina/klavulanata pri lechenii bessimptomnoi bakteriurii u beremennykh: mnogotsentrovoe randomizirovannoe prospektivnoe issledovanie. Urologiia. 2013; 5: 24–9. [in Russian]
34. Гелашвили В.В., Спивак Л.Г., Демидко Ю.Л. Медикаментозная профилактика рецидивов хронической инфекции мочевого пузыря. Вопр. урологии и андрологии. 2014; 3 (3): 31–33. / Gelashvili V.V., Spivak L.G., Demidko Iu.L. Medikamentoznaia profilaktika retsidivov khronicheskoi infektsii mochevogo puzyria. Vopr. urologii i andrologii. 2014; 3 (3): 31–33. [in Russian]
35. Moustafa F, Nguyen G, Mathevon T et al. Evaluation of the efficacy and tolerance of a short 7 day third-generation cephalosporin treatment in the management of acute pyelonephritis in young women in the emergency department. J Antimicrob Chemother 2016; pii: dkw021. [Epub ahead of print].
36. Bingen E, Bidet P, Birgy A et al. In vitro interaction between cefixime and amoxicillin-clavulanate against extended-spectrum-beta-lactamase-producing Escherichia coli causing urinary tract infection. J Clin Microbiol 2012; 50 (7): 2540–1. Doi: 10.1128/JCM.00526-12. Epub 2012 Apr 25.
37. Madhi F, Biscardi S, Bingen E et al. Combined relay therapy with oral cefixime and clavulanate for febrile urinary tract infection caused by extended-spectrum b-lactamase-producing Escherichia coli. Pediatr Infect Dis J 2013; 32 (1): 96–7. Doi: 10.1097/INF.0b013e318271f369.
38. Khosravi AD, Abasi Montazeri E, Ghorbani A, Parhizgari N. Bacterial urinary tract infection in renal transplant recipients and their antibiotic resistance pattern: A four-year study. Iran J Microbiol 2014; 6 (2): 74–8.
39. Bayram E, Bayram MT, Hiz S, Turkmen M. Cefixime-induced oculogyric crisis. Pediatr Emerg Care 2012; 28 (1): 55–6. Doi: 10.1097/PEC.0b013e31823f252d.
40. Williams GJ, Wei L, Lee A, Craig JC. Long-term antibiotics for preventing recurrent urinary tract infection in children. Cochrane Database Syst Rev 2006; 3: CD001534.
41. Кульчавеня Е.В., Краснов В.А., Скорняков С.Н. и др. Современные тенденции эпидемической ситуации по внеторакальному туберкулезу. Туберкулез и болезни легких. 2013; 12: 34–8. / Kul'chavenia E.V., Krasnov V.A., Skorniakov S.N. i dr. Sovremennye tendentsii epidemicheskoi situatsii po vnetorakal'nomu tuberkulezu. Tuberkulez i bolezni legkikh. 2013; 12: 34–8. [in Russian]
42. Кульчавеня Е.В., Брижатюк Е.В., Ковешникова Е.Ю., Свешникова Н.Н. Новые тенденции в эпидемической ситуации по туберкулезу экстраторакальных локализаций в Сибири и на Дальнем Востоке. Туберкулез и болезни легких. 2009; 10: 27–31. / Kul'chavenia E.V., Brizhatiuk E.V., Koveshnikova E.Iu., Sveshnikova N.N. Novye tendentsii v epidemicheskoi situatsii po tuberkulezu ekstratorakal'nykh lokalizatsii v Sibiri i na Dal'nem Vostoke. Tuberkulez i bolezni legkikh. 2009; 10: 27–31. [in Russian]
43. Кульчавеня Е.В., Чередниченко А.Г., Баранчукова А.А. Диагностика урогенитального туберкулеза. Урология. 2015; 5: 124–8. / Kul'chavenia E.V., Cherednichenko A.G., Baranchukova A.A. Diagnostika urogenital'nogo tuberkuleza. Urologiia. 2015; 5: 124–8. [in Russian]
44. Кульчавеня Е.В. Терапия ex juvantibus в дифференциальной диагностике туберкулеза мочеполовой системы. Туберкулез и болезни легких. 2001; 2: 29. / Kul'chavenia E.V. Terapiia ex juvantibus v differentsial'noi diagnostike tuberkuleza mochepolovoi sistemy. Tuberkulez i bolezni legkikh. 2001; 2: 29. [in Russian]
________________________________________________
2. Kul'chavenia E.V., Kholtobin D.P. Prichiny pozdnego vyiavleniia tuberkuleza mochevogo puzyria. Urologiia. 2015; 3: 29–32. [in Russian]
3. Perepanova T.S., Kozlov R.S., Dekhnich A.V. i dr. Vybor antimikrobnykh preparatov pri infektsii mochevyvodiashchikh putei. Urologiia. 2012; 2: 4–8. [in Russian]
4. Kul'chavenia E.V., Cherednichenko A.G., Neimark A.I., Shevchenko S.Iu. Chastota vstrechaemosti gospital'nykh uropatogenov i dinamika ikh chuvstvitel'nosti. Urologiia. 2015; 2: 13–6. [in Russian]
5. Qiao LD, Chen S, Yang Y et al. Characteristics of urinary tract infection pathogens and their in vitro susceptibility to antimicrobial agents in China: data from a multicenter study. BMJ Open 2013; 3 (12): e004152. Doi: 10.1136/bmjopen-2013-004152.
6. Bashir S, Sarwar Y, Ali A, Mohsin M et al. Multiple drug resistance patterns in various phylogenetic groups of uropathogenic E. coli isolated from Faisalabad region of Pakistan. Braz J Microbiol 2011; 42 (4): 1278–83. Doi: 10.1590/S1517-83822011000400005. Epub 2011 Dec 1.
7. Malmartel A, Ghasarossian C. Epidemiology of urinary tract infections, bacterial species and resistances in primary care in France. Eur J Clin Microbiol Infect Dis 2016; 35 (3): 447–51. Doi: 10.1007/s10096-015-2560-1. Epub 2016 Jan 6.
8. Martin D, Fougnot S, Grobost F et al. Prevalence of extended-spectrum beta-lactamase producing Escherichia coli in community-onset urinary tract infections in France in 2013. J Infect 2016; 72 (2): 201–6. Doi: 10.1016/j.jinf.2015.11.009. Epub 2015 Dec 15.
9. Dreshaj Sh, Doda-Ejupi T, Tolaj IQ et al. Clinical role of Cefixime in community-acquired infections. Prilozi 2011; 32 (2): 143–55.
10. Mirsoleymani SR, Salimi M, Shareghi Brojeni M et al. Bacterial pathogens and antimicrobial resistance patterns in pediatric urinary tract infections: a four-year surveillance study (2009–2012). Int J Pediatr 2014; 2014: 126142. Doi: 10.1155/2014/126142. Epub 2014 May 19.
11. Qiao LD, Chen S, Yang Y et al. Characteristics of urinary tract infection pathogens and their in vitro susceptibility to antimicrobial agents in China: data from a multicenter study. BMJ Open 2013; 3 (12): e004152. Doi: 10.1136/bmjopen-2013-004152.
12. Kresken M, Pfeifer Y, Hafner D et al. Working Party ‘Antimicrobial Resistance’ of the Paul-Ehrlich-Society for Chemotherapy. Occurrence of multidrug resistance to oral antibiotics among Escherichia coli urine isolates from outpatient departments in Germany: extended-spectrum b-lactamases and the role of fosfomycin. Int J Antimicrob Agents 2014; 44 (4): 295–300. Doi: 10.1016/j.ijantimicag.2014.05.020. Epub 2014 Jul 16.
13. Majumder MI, Ahmed T, Hossain D, Begum SA. Bacteriology and antibiotic sensitivity patterns of urinary tract infections in a tertiary hospital in Bangladesh. Mymensingh Med J 2014; 23 (1): 99–104.
14. Ahangarkani F, Rajabnia R, Shahandashti EF et al. Frequency of class 1 integron in Escherichia coli strains isolated from patients with urinary tract infections in north of Iran. Mater Sociomed 2015; 27 (1): 10–2. Doi: 10.5455/msm.2014.27.10-12. Epub 2015 Feb 21.
15. Farshad S, Ranjbar R, Japoni A et al. Microbial susceptibility, virulence factors, and plasmid profiles of uropathogenic Escherichia coli strains isolated from children in Jahrom, Iran. Arch Iran Med 2012; 15 (5): 312–6. Doi: 012155/AIM.0013.
16. Pourakbari B, Ferdosian F, Mahmoudi S et al. Increase resistant rates and ESBL production between E. coli isolates causing urinary tract infection in young patients from Iran. Braz J Microbiol 2012; 43 (2): 766–9. Doi: 10.1590/S1517-83822012000200041. Epub 2012 Jun 1.
17. Shill MC, Huda NH, Moain FB, Karmakar UK. Prevalence of uropathogens in diabetic patients and their corresponding resistance pattern: results of a survey conducted at diagnostic centers in Dhaka, Bangladesh. Oman Med J 2010; 25 (4): 282–5. Doi: 10.5001/omj.2010.82.
18 Alizadeh Taheri P, Navabi B, Khatibi E. Frequency and Susceptibility of Bacteria Caused Urinary Tract Infection in Neonates: Eight-Year Study at Neonatal Division of Bahrami Children's Hospital, Tehran Iran. Iran J Public Health 2013; 42 (10): 1126–33.
19. Lewis DA, Gumede LY, Van der Hoven LA et al. Antimicrobial susceptibility of organisms causing community-acquired urinary tract infections in Gauteng Province, South Africa. S Afr Med J 2013; 103 (6): 377–81. Doi: 10.7196/samj.6722.
20. Rafal'skii V.V., Dovgan' E.V., Derevitskii A.V. Tsefiksim: klinicheskaia farmakologiia i mesto v terapii infektsii urogenital'nogo trakta. Urologiia. 2011; 2: 63–6. [in Russian]
21. Galkin V.V., Dovgan' E.V., Kozlov S.N., Rafal'skii V.V. Tsefiksim v sravnenii s tsiprofloksatsinom pri ostrom neoslozhnennom tsistite: kliniko-ekonomicheskoe issledovanie. Klin. mikrobiologiia i antimikrobnaia khimioterapiia. 2012; 14 (1): 59–66. [in Russian]
22. Galkin V.V., Malev I.V., Dovgan' E.V. i dr. Effektivnost' i bezopasnost' tsefiksima i tsiprofloksatsina pri ostrom tsistite (mnogotsentrovoe randomizirovannoe issledovanie). Urologiia. 2011 (1): 13–6. [in Russian]
23. Korovina N.A., Mumladze E.B., Zakharova I.N. i dr. Peroral'nye tsefalosporiny III pokoleniia pri vospalitel'nykh zabolevaniiakh organov mochevoi sistemy u detei. Consilium Medicum. Pediatrics (Suppl.). 2005; 2: 17–20. [in Russian]
24. Lezhenko G.A., Pashkova E.E., Rudova E.I., Rubanova E.I. Opyt primeneniia tsefiksima v lechenii infektsii mochevoi sistemy u detei. Sovrem. pediatriia. 2013; 4 (52): 152. [in Russian]
25. Sedighi I, Solgi A, Amanati A, Alikhani MY. Choosing the correct empirical antibiotic for urinary tract infection in pediatric: Surveillance of antimicrobial susceptibility pattern of Escherichia coli by E-Test method. Iran J Microbiol 2014; 6 (6): 387–91.
26. Çoban B, Ülkü N, Kaplan H et al. Five-year assessment of causative agents and antibiotic resistances in urinary tract infections. Turk Pediatri Ars 2014; 49 (2): 124–9. Doi: 10.5152/tpa.2014.1505. eCollection 2014 Jun.
27. Loran O.B., Kogan M.I., Siniakova L.A. i dr. Ratsional'naia terapiia retsidiviruiushchikh infektsii nizhnikh mochevyvodiashchikh putei. Rezul'taty prospektivnoi nabliudatel'noi programmy po otsenke effektivnosti i bezopasnosti primeneniia preparatov Tseforal® Soliutab® i Uro-Vaskom® u patsientok s retsidiviruiushchimi neoslozhnennymi infektsiiami nizhnikh mochevyvodiashchikh putei (FLORA). Urologiia. 2015; 4: 11–8. [in Russian]
28. Kul'chavenia E.V., Breusov A.A. Effektivnost' uro-vaksoma pri retsidiviruiushchikh infektsionno-vospalitel'nykh zabolevaniiakh mochepolovoi sistemy. Urologiia. 2011; 4: 7–11. [in Russian]
29. Pistiki A, Tsaganos T, Galani I, Giamarellos-Bourboulis EJ. In Vitro Activity of Oral Cephalosporins (Cefprozil and Cefixime) Against Ciprofloxacin-Resistant Enterobacteriaceae from Community-Acquired Urinary-Tract Infections. Infect Dis Ther 2015; 4 (4): 425–32. Doi: 10.1007/s40121-015-0089-3. Epub 2015 Sep 21.
30. Rezai MS, Salehifar E, Rafiei A et al. Characterization of Multidrug Resistant Extended-Spectrum Beta-Lactamase-Producing Escherichia coli among Uropathogens of Pediatrics in North of Iran. Biomed Res Int 2015; 2015: 309478. Doi: 10.1155/2015/309478. Epub 2015 May 3.
31. Fomin V.V. Mesto tsefiksima v lechenii infektsii mochevyvodiashchei sistemy. Farmateka. 2011; 15: 69–72. [in Russian]
32. Kozyrev Iu.V., Gustovarova T.A. Bessimptomnaia bakteriuriia u beremennykh. Vestn. Smolenskoi gosudarstvennoi meditsinskoi akademii. 2011; 4: 36–42. [in Russian]
33. Rafal'skii V.V., Dovgan' E.V., Kozyrev Iu.V. i dr. Effektivnost' i bezopasnost' tsefiksima i amoksitsillina/klavulanata pri lechenii bessimptomnoi bakteriurii u beremennykh: mnogotsentrovoe randomizirovannoe prospektivnoe issledovanie. Urologiia. 2013; 5: 24–9. [in Russian]
34. Gelashvili V.V., Spivak L.G., Demidko Iu.L. Medikamentoznaia profilaktika retsidivov khronicheskoi infektsii mochevogo puzyria. Vopr. urologii i andrologii. 2014; 3 (3): 31–33. [in Russian]
35. Moustafa F, Nguyen G, Mathevon T et al. Evaluation of the efficacy and tolerance of a short 7 day third-generation cephalosporin treatment in the management of acute pyelonephritis in young women in the emergency department. J Antimicrob Chemother 2016; pii: dkw021. [Epub ahead of print].
36. Bingen E, Bidet P, Birgy A et al. In vitro interaction between cefixime and amoxicillin-clavulanate against extended-spectrum-beta-lactamase-producing Escherichia coli causing urinary tract infection. J Clin Microbiol 2012; 50 (7): 2540–1. Doi: 10.1128/JCM.00526-12. Epub 2012 Apr 25.
37. Madhi F, Biscardi S, Bingen E et al. Combined relay therapy with oral cefixime and clavulanate for febrile urinary tract infection caused by extended-spectrum b-lactamase-producing Escherichia coli. Pediatr Infect Dis J 2013; 32 (1): 96–7. Doi: 10.1097/INF.0b013e318271f369.
38. Khosravi AD, Abasi Montazeri E, Ghorbani A, Parhizgari N. Bacterial urinary tract infection in renal transplant recipients and their antibiotic resistance pattern: A four-year study. Iran J Microbiol 2014; 6 (2): 74–8.
39. Bayram E, Bayram MT, Hiz S, Turkmen M. Cefixime-induced oculogyric crisis. Pediatr Emerg Care 2012; 28 (1): 55–6. Doi: 10.1097/PEC.0b013e31823f252d.
40. Williams GJ, Wei L, Lee A, Craig JC. Long-term antibiotics for preventing recurrent urinary tract infection in children. Cochrane Database Syst Rev 2006; 3: CD001534.
41. Kul'chavenia E.V., Krasnov V.A., Skorniakov S.N. i dr. Sovremennye tendentsii epidemicheskoi situatsii po vnetorakal'nomu tuberkulezu. Tuberkulez i bolezni legkikh. 2013; 12: 34–8. [in Russian]
42. Kul'chavenia E.V., Brizhatiuk E.V., Koveshnikova E.Iu., Sveshnikova N.N. Novye tendentsii v epidemicheskoi situatsii po tuberkulezu ekstratorakal'nykh lokalizatsii v Sibiri i na Dal'nem Vostoke. Tuberkulez i bolezni legkikh. 2009; 10: 27–31. [in Russian]
43. Kul'chavenia E.V., Cherednichenko A.G., Baranchukova A.A. Diagnostika urogenital'nogo tuberkuleza. Urologiia. 2015; 5: 124–8. [in Russian]
44. Kul'chavenia E.V. Terapiia ex juvantibus v differentsial'noi diagnostike tuberkuleza mochepolovoi sistemy. Tuberkulez i bolezni legkikh. 2001; 2: 29. [in Russian]
Авторы
Е.В.Кульчавеня*
ФГБУ Новосибирский НИИ туберкулеза Минздрава России. 630040, Россия, Новосибирск, ул. Охотская, д. 81а;
ГБОУ ВПО Новосибирский государственный медицинский университет Минздрава России. 630091, Россия, Новосибирск, ул. Красный проспект, д. 52
*urotub@yandex.ru
Novosibirsk Research Institute of Tuberculosis of the Ministry of Health of the Russian Federation. 630040, Russian Federation, Novosibirsk, ul. Okhotskaia, d. 81a;
Novosibirsk State Medical University. 630091, Russian Federation, Novosibirsk, ul. Krasnyi prospekt, d. 52
*urotub@yandex.ru
ФГБУ Новосибирский НИИ туберкулеза Минздрава России. 630040, Россия, Новосибирск, ул. Охотская, д. 81а;
ГБОУ ВПО Новосибирский государственный медицинский университет Минздрава России. 630091, Россия, Новосибирск, ул. Красный проспект, д. 52
*urotub@yandex.ru
________________________________________________
Novosibirsk Research Institute of Tuberculosis of the Ministry of Health of the Russian Federation. 630040, Russian Federation, Novosibirsk, ul. Okhotskaia, d. 81a;
Novosibirsk State Medical University. 630091, Russian Federation, Novosibirsk, ul. Krasnyi prospekt, d. 52
*urotub@yandex.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.